Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment (VIKING)
Retinal Detachment With Break
About this trial
This is an interventional treatment trial for Retinal Detachment With Break focused on measuring retinal detachment, vitrectomy, gas tamponnade, suprachoroidal buckle, viscobuckle, postoperative recovery
Eligibility Criteria
Inclusion Criteria:
Patients requiring pars plana vitrectomy for the treatment of primary rhegmatogenous retinal detachment (RD) caused by a single break, or multiple breaks within one clock hour. The final determination of qualifying breaks is made at the time of surgery following 360-degree, internal, indented search using a wide-angle viewing system.
Exclusion Criteria:
- Hypersensitivity to hyaluronate or. HEALON5® PRO OVD
- Participation in another interventional study within 8 weeks of enrolment or planned to occur during this study.
- Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped prior to surgery and recommenced only after satisfactory day 1 post-operative review.
- Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.
- Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.
Study eye:
- Presence of proliferative vitreoretinopathy (PVR) or any tractional RD
- Previous vitreoretinal surgery, open-globe injury or endophthalmitis
- Aphakia
- Previous or current congenital cataract
- Previous or current suprachoroidal haemorrhage
- Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5 into the suprachoroidal space (detail the specific reason for exclusion in the source documents)
- Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to prevent an accurate assessment of retinal attachment
- Current intraocular inflammation other than mild cellular activity thought to be secondary to RD
- Current ocular or periocular infection other than blepharitis
Sites / Locations
- Sunderland Eye Infimary
- Moorfields Eye Hospital
- Guy's & St. Thomas' Hospital NHS Foundatrion Trust
- King's College Hospital NHS Foundation TrustRecruiting
- Norfolk and Norwich University Foundation Trust
- Southend University Hospital NHS Foundation Trust
Arms of the Study
Arm 1
Arm 2
Other
Active Comparator
control
treatment
Pars plana vitrectomy, retinopexy with laser or cryotherapy, and intravitreal gas tamponade.
Pars plana vitrectomy, laser retinopexy, suprachoroidal viscobuckle.